| abstract |
Provided herein are bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts, which are as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. Also provided are methods for preparing Compounds A and B or their pharmaceutically acceptable salts thereof. Compounds A and B can be used to treat and/or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases. |